Geneva, Sept. 23 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2031250356) titled 'Evaluation of efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes' on Sept. 10.
Study Type: Interventional
Study Design:
randomized controlled trial, double blind, placebo control, parallel assignment, treatment purpose
Primary Sponsor: Maruyama Hideki
Condition:
Hypercholesterolaemia
Intervention:
Drug A: Placebo
The participants will receive placebo subcutaneous on top of HIS (+/- LLT) or non-statin LLT in statin intolerant participants.
Drug B: Inclisiran
The participants will receive Inclisiran sodium 300 mg subcutaneous on top of H...